Covalon Technologies Ltd - Leaders in Infection Control Technology

Covalon Technologies Ltd - Leaders in Infection Control Technology
Share

Covalon Technologies (New Exhibitor) develops, commercializes, and licenses breakthrough products to medical companies & distributors. Covalon’s portfolio includes IV Clear® antimicrobial clear silicone adhesive dressing, antimicrobial catheter coating technology, and advanced wound products from bio-active foam dressings to biomaterial contact layers. Visit #227 to learn how to source or license Covalon’s products, and visit Industry Poster #2 “A Novel Antimicrobial Clear Silicone Dressing with Chlorhexidine and Silver” to learn more about IV Clear®.

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV), an advanced medical technologies company, today announced that it will be presenting its dual antimicrobial silicone adhesive line of products, including IV Clear™ at the Oncology Nursing Society’s (“ONS”) Annual Congress in Denver.
Covalon’s IV Clear™ is indicated to cover and...

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced the launch of its new, Centaur™ low particulate, lubricious coating designed to improve the safety and functionality of intravascular medical devices such as catheters, guidewires and delivery sheaths where the presence of...

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV), an advanced medical technologies company, announced today an update by the Company’s Chief Executive Officer on Covalon’s anticipated financial growth for fiscal 2017.
Brian Pedlar, Covalon’s CEO, stated:
“Covalon press-released a number of successes in 2016 that have truly...

Press Releases Covalon Wins $7.6 Million Twelve Month Contract to Supply ColActive Plus Advanced Wound Care Dressings to Saudi Arabia MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it has won a major contract to supply its...

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV), an advanced medical technologies company, today announced that it will be showcasing its advanced wound care line up of products at the Symposium on Advanced Wound Care Fall meeting (“SAWC Fall”) in Las Vegas from the 7th to the 9th of October.
“Covalon has supported the efforts...

MISSISSAUGA, Ontario – August 9, 2016 – /Business Wire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it has won another major contract to supply its IV Clear antimicrobial silicone vascular access dressing to Ministry of Health facilities in Saudi Arabia at a...

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it has signed a distribution agreement with Medline Industries Inc. (“Medline”), the largest privately held medical distributor in the United States, whereby Medline will be distributing Covalon-branded products,...

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it will be exhibiting at this year’s Wound, Ostomy and Continence Nurses Society (WOCN®) and the Canadian Association for Enterostomal Therapy (CAET) joint annual conference taking place on June 4-8, 2016 in Montreal,...

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that all remaining debenture holders of the convertible debentures originally issued on August 30, 2013 and maturing on August 30, 2016 have converted the debentures and related accrued interest into an aggregate of...

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced its CEO Brian Pedlar has acquired 341,502 shares of Covalon pursuant to the early conversion of a convertible debenture and related accrued interest, originally issued on August 30, 2013 and maturing on August 30, 2016.
“I...